



SEQUENCE LISTING

<110> Petropoulos, Christos J.

Parkin, Neil T.

Whitcomb, Jeanette

Huang, Wei

<120> COMPOSITIONS AND METHODS FOR EVALUATING VIRAL RECEPTOR/CO-RECEPTOR USAGE AND INHIBITORS OF VIRUS ENTRY USING RECOMBINANT VIRUS ASSAYS

<130> 2793/65166

<140> 09/874,475

D /<141> 2001-06-04

<160> 16

<170> PatentIn version 3.1

<210> 1

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: RT Primers for HIV envelope

<400> 1

ggagcattta caagcagcaa cacagc

26

<210> 2

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: RT Primers for HIV envelope

<400> 2

ttccagtcav acctcaggt a c

21

<210> 3

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: RT Primers for HIV envelope

<400> 3

agaccaatga cttayaagg

19

<210> 4

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer

<400> 4

gggctcgaga ccggtcagtg gcaatgagag tgaag

35

<210> 5

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer

<400> 5

gggctcgaga ccggtgagca gaagacagt gcaatga

37

<210> 6

<211> 36
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: PCR primer

<400> 6
gggctcgaga ccggtgagca gaagacagt gcaatg 36

<210> 7
<211> 35
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: PCR primer

<400> 7
gggtctagaa cgcgttgc ca cccatctt at agcaa 35

D/ <210> 8
<211> 38
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: PCR primer

<400> 8
gggtctagaa cgcgtccact tgccacccat bttatagc 38

<210> 9
<211> 34
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: PCR primer

<400> 9
gggtctagaa cgcgtccact tgccacccat btta 34

<210> 10
<211> 38
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: PCR primer

<400> 10
gatggtctaa gacgctgttc aatatccctg cctaactc 38

<210> 11
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Viral Entry Inhibitor Resistance Mutation

11
<400> 11
Gln Leu Leu Ser Gly Ile Val Gln Gln Gln
1 5 10

<210> 12
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Viral Entry Inhibitor Resistance Mutation

<400> 12
Gln Leu Leu Ser Ser Ile Met Gln Gln Gln
1 5 10

<210> 13
<211> 10
<212> PRT
<213> Artifical Sequence
<220>
<223> Description of Artificial Sequence: Viral Entry Inhibitor Resistance Mutation

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Where X= G or S

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Where X= V or M

D1

<400> 13
Gln Leu Leu Ser Xaa Ile Xaa Gln Gln Gln
1 5 10

<210> 14
<211> 10
<212> PRT
<213> Artifical Sequence
<220>
<223> Description of Artificial Sequence: Viral Entry Inhibitor Resistance Mutation

<400> 14
Gln Leu Leu Ser Asp Ile Val Gln Gln Gln
1 5 10

<210> 15

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Viral Entry Inhibitor Resistance Mutation

<220>

<221> MISC_FEATURE

<222> (5)..(5)

<223> Where X= G or D

<400> 15

Gln Leu Leu Ser Xaa Ile Val Gln Gln Gln
1 5 10

<210> 16

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Fusion Inhibitor Peptide

<400> 16

Tyr Thr Ser Leu Ile His Ser Leu Ile Glu Glu Ser Gln Asn Gln Gln
1 5 10 15

Glu Lys Asn Glu Gln Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu
20 25 30

Trp Asn Trp Phe
35